Gapping down
In reaction to disappointing earnings/guidance: DSW -17%, GOMO -11.3%,CRMT -11.2%, WTSL -9.9%, DAKT -5.3%, BCRX -3.9% (discloses financial outlook for 2014: Sees FY14 operating expenses in upper half of previously announced range of $48-59 mln).
M&A news: VRX -0.3% (Valeant Pharma to sell filler and toxin assets to Nestle for $1.4 billion; VRX increases merger proposal For AGN).
Select drug/biotech name showing weakness: GSK -1.6% ( Independent discusses rumors that GlaxoSmithKline may make GBP 1 bln bid for Ariad), MRK-1%, AZN -0.8% (Barron's positive on PFE after dropping AZN bid), TEVA -0.4%.
Select metals/mining stocks trading lower: RIO -1.4%, BBL -1.2%, AU -1.2%,BHP -0.7%.
Other news: ACUR -26.2% ( announces the FDA advised that data from co's AVERSION hydrocodone bitartrate with acetaminophen product candidate are insufficient to support an intranasal abuse deterrence claim), DDD -5% (is offering 5,950,000 shares of its common stock in an underwritten public offering.), MNKD-4.4% (still checking), CACH -3.3% (commences $14 mln public offering of common stock), BEE -3% (announces offering of 34 mln shares of common stock; announced that it has signed an agreement to acquire the remaining 63.6 percent ownership interest in the 757-room Hotel del Coronado for $210 mln), BCRX -2.9% (commences $100 mln public offering of common stock), BXE -2.9% (announces $250 mln bought deal financing of 25.65 mln common shares at $9.75 per share; increases FY14 CapEx budget and exit guidance), CRI -2.3% (still looking around), HCN -2.2% (announces its anticipated second quarter 2014 acquisition pipeline of ~ $414 million; announces 12 mln share common stock offering), DYAX-2% (following 28% move higher yesterday--boosted by BCRX read-thru; confirmed enrollment in trial this morning), DEO -1.5% (still checking; initiated with a Hold at Kepler), BKD -0.9% (announces secondary offering of 19.4 mln common shares by certain affiliates of Fortress Investment Group), SSYS -0.3% (following DDD offering).
Analyst comments: LOW -0.6% (Lowe's downgraded to Sell from Hold at Canaccord)
In reaction to disappointing earnings/guidance: DSW -17%, GOMO -11.3%,CRMT -11.2%, WTSL -9.9%, DAKT -5.3%, BCRX -3.9% (discloses financial outlook for 2014: Sees FY14 operating expenses in upper half of previously announced range of $48-59 mln).
M&A news: VRX -0.3% (Valeant Pharma to sell filler and toxin assets to Nestle for $1.4 billion; VRX increases merger proposal For AGN).
Select drug/biotech name showing weakness: GSK -1.6% ( Independent discusses rumors that GlaxoSmithKline may make GBP 1 bln bid for Ariad), MRK-1%, AZN -0.8% (Barron's positive on PFE after dropping AZN bid), TEVA -0.4%.
Select metals/mining stocks trading lower: RIO -1.4%, BBL -1.2%, AU -1.2%,BHP -0.7%.
Other news: ACUR -26.2% ( announces the FDA advised that data from co's AVERSION hydrocodone bitartrate with acetaminophen product candidate are insufficient to support an intranasal abuse deterrence claim), DDD -5% (is offering 5,950,000 shares of its common stock in an underwritten public offering.), MNKD-4.4% (still checking), CACH -3.3% (commences $14 mln public offering of common stock), BEE -3% (announces offering of 34 mln shares of common stock; announced that it has signed an agreement to acquire the remaining 63.6 percent ownership interest in the 757-room Hotel del Coronado for $210 mln), BCRX -2.9% (commences $100 mln public offering of common stock), BXE -2.9% (announces $250 mln bought deal financing of 25.65 mln common shares at $9.75 per share; increases FY14 CapEx budget and exit guidance), CRI -2.3% (still looking around), HCN -2.2% (announces its anticipated second quarter 2014 acquisition pipeline of ~ $414 million; announces 12 mln share common stock offering), DYAX-2% (following 28% move higher yesterday--boosted by BCRX read-thru; confirmed enrollment in trial this morning), DEO -1.5% (still checking; initiated with a Hold at Kepler), BKD -0.9% (announces secondary offering of 19.4 mln common shares by certain affiliates of Fortress Investment Group), SSYS -0.3% (following DDD offering).
Analyst comments: LOW -0.6% (Lowe's downgraded to Sell from Hold at Canaccord)